Cancer Research

Karen Vousden wins first Women in Cancer Research award

15 April 2021

Francis Crick Institute group leader Karen Vousden has been awarded the first Pezcoller-Marina Larcher Fogazzaro-EACR Women in Cancer Research Award. This new award celebrates a researcher who has demonstrated academic excellence and achievements in the field of cancer research and who has, through leadership or by example, furthered the advancement of women in cancer research. […]

Scientists discover ‘jumping’ genes can protect against blood cancers

12 April 2021

New research has uncovered an unexpected role for so-called “jumping” genes that are a source of genetic mutations responsible for many human diseases. In the new study from Children’s Medical Centre Research Institute at UT Southwestern (CRI), scientists discovered that these DNA sequences, also known as transposons, can protect against certain blood cancers. These findings, […]

Virus therapy shows promise against inoperable skin cancers

12 April 2021

Early results show that a new combination drug therapy is safe and effective against advanced skin cancer in patients who were unable to have their tumours surgically removed. Researchers say that the drug combination is among the first to demonstrate the potential value of a live common cold virus, a coxsackievirus, to infect and kill […]

Kancera’s blockers may pave the way for treatment for ovarian cancer

12 April 2021

Kancera, a company developing a new class of drugs for the treatment of inflammation and cancer, has reported preclinical research results, which show that the company’s Fractalkine blockers have the potential to disrupt cancer cells’ resistance to chemotherapy and thereby significantly improve the treatment of advanced cancer such as ovarian cancer. The disease affects over […]

First AI-designed immuno-oncology drug enters clinical trials

9 April 2021

Exscientia, an artificial intelligence (AI)-driven pharmatech company, has announced the first AI-designed molecule for immuno-oncology to enter human clinical trials, a joint venture co-invented and developed by Exscientia and Evotec. The A2a receptor antagonist, which is in development for adult patients with advanced solid tumours, includes the application of Exscientia’s next generation 3-D evolutionary AI-design […]

Blocking a protein may overcome cancer resistance to PARP inhibitors

9 April 2021

Researchers at the Francis Crick Institute have found that blocking a specific protein could increase tumour sensitivity to treatment with PARP inhibitors. Their work published in Science suggests combining treatments could lead to improved therapy for patients with inheritable breast cancers. Some cancers, including certain breast, ovarian and prostate tumours, are caused by a fault […]

Harnessing the power of IgE Technology

8 April 2021

Epsilogen is developing novel IgE antibodies to treat cancer. The company’s lead candidate,  MOv18 IgE, is in a Phase I clinical trial in folate receptor alpha positive cancer patients and is the world’s first IgE drug to enter clinical trials. Tim Wilson, CEO talks to Lu Rahman. Epsilogen was founded in April 2017 based around […]

‘Patchwork’ tumours prevalent across multiple cancer types

8 April 2021

Researchers at the Francis Crick Institute, as part of an international collaboration of scientists through the Pan-Cancer Analysis of Whole Genomes Consortium, have analysed the whole genomes of tumour samples from over 2,600 patients with different types of cancer. They identified a high prevalence of genetic diversity within individual tumours, which they further characterised. Their […]

Funding cuts could capsize cancer research in the UK

2 April 2021

Cancer research in the UK is at risk through a combination of proposed government funding cuts for UK science and the impact of the pandemic on charity funding, warns a leading cancer research institute. The Institute of Cancer Research (ICR) is revealing reductions of as much as a fifth in some of its key funding […]

Cancer drug lessens toxicity of protein from virus that causes Covid-19

29 March 2021

The University of Maryland School of Medicine (UMSOM) researchers have identified the most toxic proteins made by SARS-COV-2 and then used an FDA-approved cancer drug to blunt the viral protein’s detrimental effects. In experiments in fruit flies and human cell lines, the team discovered the cell process that the virus hijacks, illuminating new potential candidate […]

Next »

Join FREE today and become a member
of Drug Discovery World

Membership includes:

  • Full access to the website including free and gated premium content in news, articles, business, regulatory, cancer research, intelligence and more.
  • Unlimited App access: current and archived digital issues of DDW magazine with search functionality, special in App only content and links to the latest industry news and information.
  • Weekly e-newsletter, a round-up of the most interesting and pertinent industry news and developments.
  • Whitepapers, eBooks and information from trusted third parties.
Join For Free